.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,910,132

« Back to Dashboard

Claims for Patent: 7,910,132

Title:Pharmaceutical composition for the treatment of acute disorders
Abstract:A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Lidingo, SE)
Assignee: Orexo AB (Uppsala, SE)
Application Number:11/544,660
Patent Claims: 1. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition also comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or the pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid update of the fentanyl within about five minutes.

2. A method according to claim 1 wherein the fentanyl or the pharmaceutically acceptable salt thereof comprise between about 0.05 and 20 weight percent of the pharmaceutical composition.

3. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition including between about 0.05 and 20 mg of the fentanyl or the pharmaceutically acceptable salt thereof in a dose unit of the pharmaceutical composition, the pharmaceutical composition also comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or the pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes.

4. A method according to claim 1 or 3 wherein the bioadhesion and/or mucoadhesion promoting agent comprises particles having a particle size of between about 1 and 100 .mu.m.

5. A method according to claim 1 or 3 wherein the bioadhesion and/or mucoadhesion promoting agent comprises between about 0.1 and 25 weight percent of the pharmaceutical composition.

6. A method according to claim 3 wherein the bioadhesion and/or mucoadhesion promoting agent comprises particles having a particle size of between about 1 and 100 .mu.m, and wherein the bioadhesion and/or mucoadhesion promoting agent comprises between about 0.1 and 25 weight percent of the pharmaceutical composition.

7. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition including between about 0.05 and 20 mg of the fentanyl or the pharmaceutically acceptable salt thereof in a dose unit of the pharmaceutical composition, the pharmaceutical composition further comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or a pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, the bioadhesion and/or mucoadhesion promoting agent comprising particles having a particle size of between about 1 and 100 .mu.m, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes.

8. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition further comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or the pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, the bioadhesion and/or mucoadhesion promoting agent comprising particles having a particle size of between 1 and 100 .mu.m, the bioadhesion and/or mucoadhesion promoting agent comprising between about 0.1 and 25 weight percent of the pharmaceutical composition, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes.

9. A method according to claim 7 wherein the bioadhesion and/or mucoadhesion promoting agent comprise between about 0.1 and 25 weight percent of the pharmaceutical composition.

10. A method according to claim 1 or 3 or 7 or 8 wherein the pharmaceutical composition comprises a pharmaceutically effective amount of fentanyl citrate, and wherein the sublingual administration provided allows the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes.

11. A method according to claim 8 wherein the fentanyl or the pharmaceutically acceptable salt thereof comprise between about 0.05 and 20 weight percent of the pharmaceutical composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc